Poly(palmitoyl- l-hydroxyproline ester) microspheres as potential oral controlled drug delivery system

A new type of carrier using poly(palmitoyl- l-hydroxyproline ester) (PPH) [IUPAC name: poly((1-palmitoyl-4,2-pyrrolidinediyl)carbonyloxy)], a poly(amino acid) is described. The polymer is synthesized by conventional method and the microspheres were prepared by solvent evaporation technique for appli...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 1997-04, Vol.149 (1), p.107-114
Main Authors: Madhan Kumar, A.B., Panduranga Rao, K.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Drug release
General pharmacology
Medical sciences
Microspheres
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Poly(palmitoyl- l-hydroxyproline ester)
Rifampicin
Solvent evaporation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new type of carrier using poly(palmitoyl- l-hydroxyproline ester) (PPH) [IUPAC name: poly((1-palmitoyl-4,2-pyrrolidinediyl)carbonyloxy)], a poly(amino acid) is described. The polymer is synthesized by conventional method and the microspheres were prepared by solvent evaporation technique for application in drug delivery system. Microspheres with different sizes were prepared by varying certain formulation and technological parameters and their distributive stabilities under physiological conditions were studied. The microspheres were characterized by DSC, optical and laser particle size analysis. A model drug, rifampicin (antituberculosis drug) was entrapped in the microspheres and the in vitro release studies were performed in pH 7.4 and pH 1.5 buffer media. The pH value seemed to have some influence on the dissolution rate of the rifampicin-containing microspheres. Dissolution experiments using rifampicin indicated the possibility of using PPH microspheres with other hydrophobic drugs.
ISSN:0378-5173
1873-3476
DOI:10.1016/S0378-5173(96)04856-9